Skip to main content

Response Biomedical Files for $7.8M Raise

NEW YORK (GenomeWeb News) – Response Biomedical has filed with Canadian regulators to raise C$8 million (US$7.8 million), the company said this week.

Proceeds from the offering will be directed at continued product development, sales and marketing, working capital, operating losses, and other general corporate purposes.

The proposed terms of the offering, which is expected to be completed before the end of the year, will entitle each shareholder to a certain number of rights for each common share of Response Biomedical stock. Each right will be exercisable for one unit, consisting of once common share and one common share purchase warrant.

The price to buy each right is anticipated to be equal to half of the lesser of C$.1493 and the volume weighted average trading price for the company's stock during the 10 days leading up to and including the date of the final prospectus related to the offering.

The Vancouver, British molecular diagnostics firm also said that it has entered into a letter of intent with OrbiMed Advisors to commit at least C$5 million in units, not otherwise purchased pursuant to the exercise of rights under the offering.

Last week, Response Biomedical filed its completed restated financial statements for full-year 2011 and the first two quarters of 2011.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.